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Abstract 
lndolicidin, a cationic tridecapeptide amide isolated from the granules of bovine neutrophils, has been found to possess potent 
antimicrobial activity in vitro but its nonselective toxicity could restrict its therapeutic utility. We found that the concentration at which 
indolicidin disrupts washed human red blood cell membranes coincided with the concentration at which indolicidin self associates, 
Because of a preponderance of hydrophobic residues, we believed that indolicidin would partition into liposomes which would restrict its 
exchange with biological tissues and consequently reduce its toxicity. Fluorescence spectroscopy of indolicidin added to 100 nm 
liposomes comprised of POPC, POPC/cholesterol (60:40 mol%), DPPC, or DPPC/cholesterol (60:40) revealed a large blue-shift and an 
increase in intensity of the emission profile indicating insertion into the bilayer. Of the lipids tested, POPC exhibited the highest degree of 
indolicidin binding as determined by fluorescence and encapsulation efficiency. By sequestering indolicidin within the lipid bilayer of 100 
nm POPC liposomes we significantly reduced its toxicity to CHO/K1 cells. Likewise, the systemic toxicity of liposomal indolicidin in 
Balb/c mice was decreased dramatically relative to aqueous olutions; the maximum dose at which no deaths occurred was 0.4 mg/kg 
for free indolicidin versus 40 mg/kg for indolicidin-POPC. Because of this decrease in toxicity, we were able to administer liposomally 
encapsulated material at significantly higher concentrations than unencapsulated aqueous material and achieve fficacy in treating animals 
systemically infected with Aspergillus fumigatus. Liposomal but not free indolicidin was found to be effective in obtaining cures. This 
report is the first description of the in vivo therapeutic activity of a neutrophil-derived antimicrobial peptide and suggests that liposomal 
treatment modalities will provide effective strategies for endowing this class of compounds with pharmacological utility. 
Keywords: Antimicrobial agent; Antifungal agent; Liposome; Peptide; Indolicidin 
1. Introduction 
H-Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH 2 
lndolicidin is an antimicrobial tridecapeptide amide iso- 
lated from the cytoplasmic granules of bovine neutrophils 
[ 1,2]. Structurally, indolicidin is unique among known host 
Abbreviations: POPC, I-palmitoyl-2-oleoylphosphatidylcholine; 
DPPC, 1,2-dipalmitoylphosphatidylcholine; FATMLVs, freeze-thaw 
multilamellar vesicles; LUVETs, large unilamellar vesicles by extrusion 
technique; CHO, Chinese hamster ovary; LDI0, lethal dose 10%, dose at 
which 10% animals die; 1C50, inhibitory concentration 50%, dose at 
which 50% inhibition occurs; PBS, phosphate-buffered saline; RBC, red 
blood cell; FBS, fetal bovine serum. 
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defense peptides due to its high (39%) tryptophan content 
[3]. 
The mechanism of action of indolicidin is not clearly 
understood but may involve the disruption of cell mem- 
branes. Thus, in solution, in addition to a broad spectrum 
of antifungal and antibacterial activities, it is also toxic to 
mammalian cells. This lack of selectivity could signifi- 
cantly restrict its clinical use. 
In recent years, much interest has centered upon the 
therapeutic applications of liposomes and lipid complexes 
[4]. In many cases these systems have effectively reduced 
the toxicity of important drugs without significant compro- 
mise to efficacy [5,6]. In fact, as determined in recent 
clinical trials involving both water and lipid soluble com- 
pounds [7-9], this approach as permitted osing protocols 
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that would otherwise produce toxicity and consequently 
has opened new therapeutic opportunities. Now we de- 
scribe a liposome formulation of indolicidin and compare 
its toxicity in vitro and in vivo to aqueous indolicidin. 
Furthermore, we compare the efficacy of a single maxi- 
mally tolerated intravenous dose of liposomal indolicidin 
to aqueous indolicidin in a mouse model of systemic 
aspergillosis. Taken together, these data demonstrate hat a 
striking reduction in overall toxicity and improvement in
therapeutic efficacy can be achieved for this compound by 
providing it with a liposomal carrier system. Such liposo- 
mal systems may well provide heretofore not available 
clinical opportunities for antimicrobial peptides. 
2. Materials and methods 
2.1. Chemicals 
Indolicidin (acetate salt), was synthesized [2] and puri- 
fied as previously described [2,10]. Preparations were de- 
termined to be homogeneous by reversed phase HPLC, 
acid-urea PAGE, FAB-MS and by sequence analysis. Final 
stock preparations were quantified by amino acid analysis 
prior to lyophilization, l-Palmitoyl-2-oleoyliphosphatidyl- 
choline (POPC) and 1,2-dipalmitoylphospbatidylcholine 
(DPPC) were purchased from Avanti Polar Lipids (Bir- 
mingham, Alabama). Cholesterol, Hepes, and NaC1 were 
purchased from Sigma Chemical (St. Louis, MO) and all 
other reagents were of the highest purity available. 
2.2. Biochemical assays 
Indolicidin concentrations were measured spectrophoto- 
metrically by dissolving samples in ethanol and comparing 
absorbance to A2s 0 of an amino acid analyzed standard 
solution. In these studies we used a Shimadzu Model 160 
spectrophotometer (Shimadzu, Columbia, MD, USA). 
Phospholipid concentration was determined by the proce- 
dure of Chert [ 11 ]. 
2.3. Preparation of liposomes 
Freeze-thaw multilamellar vesicles (FATMLVs) were 
made as previously described [12]. Briefly, lipid in chloro- 
form was dried to a thin film using a rotary evaporator and 
the thin dried film was hydrated with a buffer comprised 
of 10 mM Hepes and 150 mM NaC1 at pH 7,4. For 
liposomes containing indolicidin the lipid and indolicidin 
were co-dissolved in organic solvent by first dissolving 
indolicidin in methanol and then adding the lipid in chloro- 
form. After evaporation and rehydration, the liposome 
suspensions were frozen (liquid nitrogen) and thawed (40°C 
water bath) five times, thereby producing freeze-thaw 
multilamellar vesicles (FATMLVs) [12]. To make large 
unilamellar liposomes by extrusion (LUVETs), the FATM- 
LVs were passed 10 times through 0.1 /xm double stacked 
Nuclepore filters using an extruder device (Lipex Biomem- 
branes Vancouver, BC, Canada). For samples containing 
DPPC the extrusion was done at 50°C. Sizes of liposomes 
were determined by light scattering using a Nicomp Model 
270/370 Submicron Particle Sizer. For all studies, LU- 
VETs had a mean diameter between 98 and 118 nm. 
2.4. Spectroscopy 
Right angle light scattering of indolicidin in buffer 
solution (no liposomes) was performed using a PTI Alfa 
Spectrofluorometer (PTI Instruments, Princeton, N J). Exci- 
tation wavelength was set at 500 nm. Scattered light was 
quantitated by scanning between 460 and 540 nm (maxi- 
mum at 500 nm), and the area under the curve was plotted 
versus indolicidin concentration. Spectrophotometric anal- 
ysis demonstrated that indolicidin does not absorb light 
between 460 and 540 nm. 
The fluorescence of indolicidin in buffer solution (10 
mM Hepes, 150 mM NaC1 at pH 7.4) was measured using 
the above mentioned spectrofluorometer and quartz cu- 
vettes. The excitation maximum was found to be 285 rim. 
With the excitation wavelength fixed at 285 nm, emission 
spectra were taken between 320 and 450 nm (emission 
maximum at 353 nm). The area under the emission curve 
was plotted versus indolicidin concentration. Indolicidin- 
free liposomes (100 nm diameter) were prepared as de- 
scribed above. The emission spectra of buffer, indolicidin- 
free liposomes in buffer, and indolicidin in buffer with and 
without liposomes (0.5 p.g/ml indolicidin and 0.1 mg/ml 
lipid) were measured between 300 nm and 500 nm (ex- 
cited at 285 nm). Spectra of the buffer solution alone and 
empty liposomes were subtracted from the appropriate 
indolicidin spectra to correct for scattering. 
2.5. Hemolytic acticitv 
Hemolysis was measured as previously described [13]. 
Briefly, an equal volume of sample was mixed with washed 
4% (v/v)  human red blood cells in phosphate-buffered 
saline and incubated with constant agitation for 20 h at 
37°C. Following low speed centrifugation (~ 1000 × g for 
10 rain) an aliquot of the supernatant was taken and 
diluted with buffer solution and the absorbance at 550 nm 
measured. The controls for 0 and 100% hemolysis were 
established by mixing the 4% red blood suspension l:l 
with either buffer solution or distilled water, respectively. 
2.6. Cytotoxicity 
The specific inhibition of in vitro proliferation of 
CHO/K1 cells by free, liposomal indolicidin or empty 
(indolicidin-free) liposomes was monitored by a 
[3H]thymidine incorporation assay [14]. In brief, 2. 10 4 
cells/well were plated onto 96 well flat-bottomed mi- 
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crotiter plates in RMP-1640 medium supplemented with 
10% FBS, and kept at 37°C in a humidified atmosphere of
5% CO 2. Cells were exposed to various concentrations of 
either empty (indolicidin-free) liposomes, phosphate- 
buffered saline (PBS), free indolicidin or liposomal indoli- 
cidin and cultured for 4 h at 37°C. Cells treated with 
various formulations of indolicidin were incubated for 
another 8 h with an added 0.5 /xCi/well of [3H]thymidine 
(specific activity 50 Ci/mmol) (ICN Biomedicals, USA). 
Cells were harvested on 934AH filter paper with a Brandel 
M-96 harvester (Brandel, MD, USA). [3H]Thymidine in- 
corporation was determined by liquid scintillation count- 
ing. 
2.7. Animal models 
For in vivo toxicity, groups of male Balb/c mice 
(5/group, weight 20-22 g) were injected with various 
doses of free indolicidin (0.4-12 mg/kg) or liposomal 
indolicidin (20-160 mg/kg) in 0.2 ml of pyrogen-free 
saline via the tail vein. Normal saline or suspensions of 
indolicidin-free liposomes were also injected in separate 
groups of mice. The mice were observed for 14 days to 
determine long term consequences although death usually 
occurred within 15 min. The LDt0 dose was estimated 
according to method of Litchfield and Wilcoxon [15]. 
For in vivo efficacy, an infected animal model was 
established using Aspergillusfumigatus strain 36607 which 
was obtained from ATCC and maintained in Malt extract 
agar medium (Blakeslee's Formula). In preliminary experi- 
ments three groups (10/group) of male Balb/c mice 
(body weight 18-22 g) were injected via the tail vein with 
8"  l07' 4"  107, or  2"  107 spores of A. fumigatus sus- 
pended in 0.2 ml sterile phosphate-buffered saline (PBS). 
Animals treated with either 8. 107 or  4 .  107 spores died 
within 2 days but animals treated with 2-107 fungal 
spores survived for 4-5 days. In all subsequent experi- 
ments, we used a dose of 2 • 107 A. fumigatus pores for 
infection. 
Five groups of mice (10/group) were injected with 
2 • l07 A. fumigatus pores administered intravenously via 
the tail vein. 6 h following infection the first and second 
groups received either 2 mg/kg free indolicidin or liposo- 
mal indolicidin via the tail vein. The third and fourth 
groups were given either 40 mg/kg liposomal indolicidin 
or the same amount of lipid dosed as empty liposomes. An 
additional control group was injected with 0.2 ml PBS. 
The therapeutic efficacy of free indolicidin and liposomal 
indolicidin was measured by quantifying percent surviving 
animals as a function of time after infection. 
3. Results and discussion 
Although indolicidin is highly soluble in water (_> 20 
mg/ml) we explored the possibility that because of its 
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Fig. 1. Light scattering (90 ° angle) of aqueous indolicidin. Indolicidin was 
placed in buffer solution (10 mM Hepes, 150 mM NaC1 at pH 7.4) and 
the amount of light scattered at 90 ° was measured using a spectrofluorom- 
eter with excitation and emission wavelengths set at 500 nm. The lines 
are linear regression fits of the first five data points and the last three data 
points. The intersection occurs at ~ 50 /~g/ml indolicidin. 
preponderance of hydrophobic residues, indolicidin might 
self associate at the higher concentrations. We found the 
90 ° angle light scattering of this molecule increased ra- 
matically when its concentration exceeded approx• 50 
/xg/ml (Fig. 1). In similar experiments we plotted the area 
under the curve of the fluorescence mission profile of 
indolicidin scanned over 325-450 nm (excited at 285 nm) 
as a function of concentration a d again found a disconti- 
nuity near 50 /zg/ml confirming a concentration depen- 
dent self association of this peptide (Fig. 2). The impor- 
tance of this self association became apparent when we 
examined indolicidin toxicity. Interestingly, the concentra- 
tion corresponding to self association coincided with the 
onset of indolicidin in vitro hemolytic activity (Fig. 3) 
mirroring activity not unexpected for a membrane active 
agent [16]. 
The molecular details of how indolicidin permeabilizes 
RBC membranes were unclear but its character, adsorption 
and disruption of membranes invited comparison to deter- 
gents and their permeabilization of membranes [16]. In 
particular, the self association of indolicidin suggested that 
it might partition into bilayer membranes to avoid aqueous 
exposure of its hydrophobic domains. Using this strategy, 
we believed we could entrap indolicidin into liposomes 
where its availability and therefore acute toxicity would be 
reduced making it a more appealing candidate for antimi- 
crobial therapy. To gauge the extent o which the peptide 
would interact with various membranes, we mixed indoli- 
cidin with preformed single lamellar liposomes (100 nm) 
112 L Ahmad et al. / Biochimica et Biophysica Acta 1237 (1995) 109-114 
30 i , i • i , , i  i 
25 
.zx 
20 . . . . . . . .  . . . - - "  
~ 15 
--= l0 gr, 
..> 
0 5'0 1;0 1;0 2;0 
Indolicidin (p.g/ml) 
Fig. 2. Relative fluorescence of aqueous indolicidin. Indolicidin was 
added to buffer solution and the fluorescence emission spectrum scanned 
between 320 and 450 nm with the excitation wavelength set at 285 nm. 
The relative fluorescence spectra (areas under the curve for the emission 
spectra) are plotted as a function of indolicidin concentration. The solid 
line is a linear regression fit of the first 13 data points, r = 0.999 (the 
highest hree indolicidin concentrations were excluded). The deviation 
from linearity occurred above 50 /xg/ml indolicidin which could be the 
result of self quenching but is more likely due to an inner filter effect 
derived from the increased light scattering. 
at room temperature comprised of either solid (DPPC) or 
fluid phase (POPC) lipid, and examined fluorescence emis- 
sion profiles (Fig. 4). The blue-shift in emission maximum, 
as well as increase in fluorescent intensity suggested the 
partitioning of tryptophan residues from buffer solution 
into the comparatively ess polar environment of the lipid 
bilayer. 
Although qualitatively it appeared that POPC liposomes 
were afforded the largest degree of partitioning, no quanti- 
tative assessment could be made from the fluorescence 
data. However, when we examined the retention of indoli- 
cidin by POPC liposomes formed by the freeze thaw 
procedure, we found that essentially all of the added 
indolicidin was associated whereas only ~ 20% entrap- 
ment would be expected based on aqueous distributions. 
Similarly made dispersions of DPPC/cholesterol (60:40) 
liposomes, the lipid system showing the least indolicidin 
adsorption/penetration by fluorescence, retained only ~ 
20% of the initial amount of indolicidin consistent with 
entrapment into the aqueous volume of these systems. In 
this study, the initial aqueous concentrations of indolicidin 
and lipid were held at 0.33 mg/ml and 20 mg/ml, 
respectively, and repeated centrifugation with supernatant 
replacement was used to remove unbound/unentrapped 
material and the indolicidin to lipid ratio determined as 
described in Materials and methods. This preference for 
partitioning into fluid phase bilayers is not unique to 
indolicidin but rather has been shown for other amphi- 
pathic molecules (i.e., anesthetics [17,181). Inclusion of 
cholesterol in POPC and DPPC membranes reduced the 
fluorescence intensity of indolicidin. Because we do not 
know the depth of indolicidin penetration i to the bilayer 
we can not fully assess the role of chain fluidity (as 
affected by cholesterol) upon indolicidin partitioning. 
However, consistent with our results, cholesterol has been 
shown to reduce the partitioning of anesthetic into both 
fluid and gel phase bilayers [18] suggesting that acyl chain 
mobility may have only marginal impact upon the ability 
of these classes of agents to associate with membranes. 
We realized at this point that we could take advantage 
of indolicidin's high affinity for POPC bilayer membranes 
and entrap it with high efficiency (100%). To make the 
sample size more homogeneous we next turned to extru- 
sion to make the liposomes reproducibly at 100 nm mean 
diameter. Using this 100 nm POPC formulation we as- 
sessed the cytotoxicity of free indolicidin and liposome- 
bound indolicidin against normal CHO/K1 cells using a 
[3H]thymidine incorporation assay (Fig. 5). Comparison 
between free indolicidin and liposomal indolicidin clearly 
showed that POPC associated indolicidin was less toxic to 
normal mammalian cells. However, there was some toxic- 
ity observed when higher concentrations of liposomal in- 
dolicidin were used. The 50% growth inhibitory concentra- 
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Fig. 3. Hemolytic activity of aqueous indolicidin. Indolicidin was incu- 
bated with washed human red blood cells for 20 h at 37°C (see Materials 
and methods for details). Error bars represent the standard eviation for 
three experiments (note: each experiment is the average of two to three 
replicates). Hemolytic activity increased ramatically between 10 and 100 
~g/ml  indolicidin. Percent hemolysis values greater than 100% were 
obtained because indolicidin was apparently more efficient than the 
distilled water control at lysing red blood cells; the '100%' control using 
distilled water does not yield complete hemolysis but is used for compar- 
ative purposes. 
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Fig• 4. Fluorescence emission profiles of indolicidin in 100 nm liposomes 
and free indolicidin in buffer solution. Spectra from highest o lowest 
intensity are of indolicidin in POPC liposomes (--) ,  in POPC/cholesterol 
(60:40 mole ratio) liposomes ( - . - ) ,  in DPPC liposomes ( - - - ) ,  
DPPC/cholesterol (60:40) liposomes ( . . . . . .  ), and in buffer solution 
( . . . .  ). Lipid and indolicidin concentrations were 0.1 mg/ml and 5 
/xg/ml, respectively. The emission maximum is blue shifted by 18 nm 
for indolicidin in POPC liposomes (A,,~ = 340.5 nm) as compared to 
buffer solution (Am~  = 358.5 nm). Each spectrum is the average of five 
scans .  
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Fig. 5. Growth inhibition of CHO/KI  cells by free indolicidin and 
liposomal indolicidin after 12 h as a function of indolicidin concentration. 
Cells were first incubated for 4 h and then 0.5 /xCi/well [3H]thymidine 
was added with a further 8 h incubation in media. Indolicidin comprised 5 
mol% of a mixture with POPC 100 nm LUVETs. Controls were run using 
PBS (crosshatch lines) and empty liposomes (horizontal lines). Results 
are expressed as the means + S.D. of eight replicates. 
Table 1 
Indolicidin in vivo toxicity in Balb/c mice 
Indolicidin Mortality 
(mg/kg) 
0.4 0/5  
1.2 1/5 
4.0 3/5 
12.0 5/5 
Four groups of mice (5/group) were injected with various doses of free 
indolicidin in 0.2 ml of pyrogen-free saline via the tail vein. Normal 
saline was also injected in a separate group of mice but no toxicity was 
observed• 
tion (1C50) of free indolicidin was much lower than that of 
liposomal indolicidin, 30 versus 479 /xg/ml. The higher 
ICs0 for liposomal indolicidin was probably a result of the 
sequestration of indolicidin within the liposomes which 
would restrict he amount of material available to interact 
with cells. Results similar to those reported for the thymi- 
dine incorporation assay were obtained from an assay in 
which CHO/KI  cell proliferation was measured irectly 
by counting cell numbers (not shown). 
We next evaluated the POPC liposomal indolicidin 
formulation in Balb/c mice (see Table 2). The data from 
Table 1 Table 2were used to estimate the LDI0 of free 
indolicidin. Free indolicidin had an estimated LD10 of 0.9 
mg/kg whereas liposomal indolicidin had a significantly 
reduced toxicity (LDj0 > 59 mg/kg). Symptoms reflecting 
the acute toxicity of free indolicidin and liposomal indoli- 
cidin were similar and included gasping and convulsions 
most likely neurological in origin• These in vivo results 
were consistent with the in vitro CHO/K1 data. We 
postulate that the reduced toxicity of indolicidin entrapped 
in liposomes may be due to (i) altered interactions of 
indolicidin with mammalian cells or (ii) decreased avail- 
ability because liposomes release entrapped indolicidin 
slowly, restricting its concentration below that required for 
deleterious effects. 
Table 2 
Toxicity of liposomal indolicidin in Balb/c mice 
lndolicidin Mortality 
(mg/kg) 
20 0/5  
40 0/5 
80 J/5 
150 4/5  
160 5/5 
Five groups of mice (5/group) were injected with various doses of 
liposomal indolicidin (5 tool% in POPC 100 nm LUVETs) in 0.2 ml of 
pyrogen-free saline via the tail vein. Normal saline and indolicidin-free 
100 nm POPC liposomes were also injected in separate groups of mice 
but no toxicity was observed with these controls. To find the maximum 
mol%age of indolicidin that could be introduced safely into mice we 
escalated the mol% of indolicidin (up to 15 mol%) in POPC liposomes. 
However, these systems howed immediate lethality in mice (data not 
shown). This lethality was not observed at similar doses when indolicidin 
comprised up to 5 mol% of the mixture with POPC liposomes. 
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Fig. 6. Therapeutic efficacy of a single dose of free indolicidin and 
liposomal indolicidin against systemic aspergillosis in Balb/c mice. 
Liposomes were 100 nm POPC LUVETs containing indolicidin at 5 
mol%. Mice (10/group) were infected intravenously with 2.107 A. 
fumigatus pores via tail vein. After 6 h of spore challenge, the first and 
second groups received 2 mg/kg of either free indolicidin (A) or 
liposomal indolicidin (v )  intravenously. The third and fourth groups 
were treated either with 40 mg/kg of liposomal indolicidin (O) or with a 
similar dose of indolicidin-free liposomes (C)). The fifth group was 
treated with 0.2 ml of 10 mM Hepes-buffered saline (11). 
The reduced toxicity of the liposomal formulation en- 
couraged us to develop an animal model for systemic 
fungal infection to evaluate and compare the therapeutic 
efficacy of free indolicidin and liposomal indolicidin. Two 
mg/kg of free indolicidin had no significant effect on the 
survival of mice infected with A. fumigatus (nor did this 
dose appear to cause any toxic deaths in infected animals) 
whereas 20% of mice treated with a similar dose of 
liposomal indolicidin survived 10 days (Fig. 6). Although 
escalating the dose of free indolicidin was prohibited by its 
toxicity, Fig. 6 shows that survival was considerably in- 
creased by treating the animals with 40 mg/kg of liposo- 
mal indolicidin; a 30% long term survival was achieved. 
The surviving mice were killed after the 25th day with no 
sign of disease in their lungs upon gross pathological 
inspection. Lungs of the terminated mice were plated on 
Malt extract agar medium and no A. fumigatus was de- 
tected after 3 days of incubation at 30°C. It is well 
documented that liposomal association can improve the 
therapeutic ndex of systemically toxic drugs [4] but the 
exact mechanism for improved therapeutic efficacy with 
liposomal indolicidin is not clearly understood. Possible 
explanations for reduced toxicity and improved efficacy 
may include the rapid uptake of liposomes by macrophages 
giving indolicidin less opportunity to be systemically ac- 
tive. In disease, the migration of macrophages to the site of 
infection would provide a mechanism for accomplishing 
high local concentrations of indolicidin at target sites. 
Alternatively, uptake of liposomal indolicidin by 
macrophages might augment their activity. 
The observations presented here demonstrate the useful- 
ness of liposomes as carriers in improving the therapeutic 
index of indolicidin and perhaps other neutrophil-derived 
antimicrobial peptides in the treatment of fungal infections. 
The therapeutic utility of intravenously infused free indoli- 
cidin appears to be limited due to its toxicity. However, 
the in vivo study described here demonstrates for the first 
time that a non-toxic liposomal formulation of indolicidin 
is efficacious in treating systemic murine aspergillosis. 
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